<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926107</url>
  </required_header>
  <id_info>
    <org_study_id>HE 4/09</org_study_id>
    <secondary_id>2008-007925-38</secondary_id>
    <nct_id>NCT00926107</nct_id>
  </id_info>
  <brief_title>Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse</brief_title>
  <official_title>Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy of Temsirolimus in patients
      with ovarian cancer with CA125 only relapse after first-line platinum-based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in
    the first two years of patients enrolment
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical progression free survival.</measure>
    <time_frame>6-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS),Survival, CA125 response rate, Safety</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus 25mg weekly until clinical progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologic proof of epithelial ovarian,fallopian or peritoneal carcinoma of the
             following histological types:serous, endometrioid, mucinous, clear cell, low
             differentiation.

          2. Age 18 years or older

          3. Patients should have received first-line platinum based chemotherapy

          4. Documented CA125 progression according to GCIC criteria.

          5. No evidence of measurable or evaluable disease.

          6. Provision of written informed consent

          7. ECOG PS 0-2

          8. Life expectancy of greater than 12 weeks

          9. WBC&gt;4000/μl, platelets &gt; 100,000/μl and a hemoglobin level &gt; 9.5 g/dl. Adequate
             baseline hepatic function, defined as a total bilirubin level &lt; 2 mg/dl, SGPT and SGOT
             &lt; 2.5 times the upper limits of normal. Creatinine &lt; 1.5 mg/dl or creatinine clearance
             &gt; 60 ml/min.

         10. All females of childbearing potential must have a negative serum or urine pregnancy
             test obtained within 2 days prior to initiation of treatment and use effective
             contraception during the period of therapy.

         11. At least one month from the last chemotherapy administration.

         12. Provision of adequate paraffin-embedded tumor tissue for translational studies
             (optional).

        Exclusion Criteria:

          1. Other histological types (germ cell, granulose tumors etc)

          2. History of atrial or ventricular arrhythmias and/or history of congestive heart
             failure, even if medically controlled. History of clinical and
             electrocardiographically documented myocardial infarction within the last 6 months
             from study entry

          3. Any evidence of clinically active interstitial lung disease (patients with chronic
             stable radiographic changes who are asymptomatic need not be excluded)

          4. Pre-existing motor or sensory neurotoxicity grade 2 according to the WHO criteria
             (intolerable paresthesia and/or marked motor loss or worse)

          5. History of any treatment for CA125 relapse

          6. Known, severe hypersensitivity to temsirolimus or any of the excipients of this
             product

          7. Other coexisting malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma or cervical cancer in situ

          8. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          9. As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (eg unstable or uncompensated respiratory, cardiac, hepatic or renal disease)

         10. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5
             times the ULRR.

         11. Active infection or evidence of any other significant clinical disorder or laboratory
             finding that makes it undesirable for the patient to participate in the trial/ receive
             protocol treatment

         12. Concomitant use of Cyp3 A inducers (phenytoin, carbamazepine, rifampicin, barbiturates
             or St John's Wort) should be avoided and as should treatment with strong CyP 3A
             inhibitors

         13. Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             trial treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Alexandra&quot; Hospital, Dept. of Clinical Therapeutics, Oncology</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Attikon&quot; University Hospital, 2nd Dept. of Internal Medicine-Propaedeutic, Oncology Section</name>
      <address>
        <city>Athens</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital, 1st Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital, 2nd Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chania General Hospital, Oncology Dept.</name>
      <address>
        <city>Chania</city>
        <zip>73100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ioannina University Hospital, Dept. of Medical Oncology</name>
      <address>
        <city>Ioannina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larissa University Hospital, Oncology Dept.</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras, Oncology Dept</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, 1st Dept. of Medical Oncology</name>
      <address>
        <city>Pireaus</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, 2nd Dept. of Medical Oncology</name>
      <address>
        <city>Pireaus</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Papageorgiou&quot; General Hospital, Dept. of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

